Cyclic nucleotide-gated cation channel alpha-3 (CNGA3) (CNGA3)

Cyclic nucleotide-gated cation channel alpha-3 (CNGA3) is a pore-forming subunit of the cyclic nucleotide-gated (CNG) ion channels found exclusively in the cone photoreceptors of the retina [2, 4]. These channels are essential for phototransduction, the process by which light is converted into electrical signals; they remain open in the dark due to high cGMP levels and close upon light-induced cGMP hydrolysis, leading to cell hyperpolarization [2, 14]. Mutations in the CNGA3 gene are a leading cause of achromatopsia, an autosomal recessive condition characterized by total color blindness, poor visual acuity, and extreme photophobia [2, 10]. As a therapeutic target, CNGA3 is the focus of gene augmentation strategies that utilize adeno-associated virus (AAV) vectors to deliver functional copies of the gene to the subretinal space [6, 13]. Clinical trials have demonstrated that restoring CNGA3 expression can improve cone-mediated vision and light tolerance, although challenges remain regarding the optimal therapeutic window and potential interference from endogenous mutant proteins [13, 18].

Other names

ACHM2CCNC1CCNCalphaCNCG3CNG3Cyclic nucleotide-gated channel alpha 3Cyclic nucleotide-gated channel subunit alpha 3Cone photoreceptor cGMP-gated channel subunit alpha

Gene augmentation therapy (delivering a functional copy of the CNGA3 gene via an adeno-associated virus vector to restore cone photoreceptor function)